Australian researchers to deliver world's first Respiratory Syncytial Virus Vaccine

A team of Australian researchers is close to completing a 20-year project to develop the world's first vaccine to prevent respiratory syncytial virus (RSV), a breakthrough that could save thousands of children every year.

 

 

According to research published in Lancet Infectious Diseases on Wednesday, Niversimab is a safe and effective monoclonal antibody treatment for babies.

 

 

Researchers expect the treatment to be available within 12 months, followed closely by a maternal vaccine for newborns that protects them against RSV during pregnancy.

 

 

University of Western Australia professor Peter Richmond, head of the Vaccine Trials Group and dean of the School of Paediatrics, said Niversimab had just completed phase three clinical trials.

 

 

"It should be approved for use as the very first RSV prevention treatment in the United States and Europe by the end of 2022 or the beginning of 2023, " he said.

 

 

Each year, RSV causes more than 100,000 deaths and 3.6 million hospitalizations worldwide. Infection of the lungs and airways can result in life-threatening complications, such as pneumonia and bronchiolitis.

 

 

Despite its high burden of disease, attempts to develop an RSV vaccine have been unsuccessful for more than 50 years. Due to both the difficulty of immunizing very young infants, who often respond inadequately to vaccinations, and the fact that past experimental vaccines have triggered more serious infections, progress has been hindered.

 

 

The team was especially excited given the context of their own phases 1 and 2 studies dating back more than a decade, "It has been a long journey to get here," Richmond said. "As a paediatrician who has treated sick babies with RSV for over 30 years, the idea that we can prevent a large portion of these illnesses is fantastic, and I feel fortunate to have been involved."

 

 

Currently, Richmond and his colleagues are assessing parental awareness of RSV in order to develop educational materials.

 

 

The GCP course is an excellent way to expand your horizons, regardless of whether you are tired of your current job or dream of working in clinical trials. In addition to making a difference in people's lives, you'll also be able to work towards a financially rewarding career.

 

 

Feel free to browse our website for more information about our courses. Let us know what you think about our courses in order to move forward with them.

 

 

You can also contact us through our website's contact page. We are always happy to discuss options with you, so reach out to us today.


LinkedIn

     Email

Share on LinkedIn

    

Share via Email

                                 

                                    +21,000 STUDENTS        +9,400 COMPANIES          +100 COUNTRIES

 

Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo